Copyright Reports & Markets. All rights reserved.

Global Esophageal Cancer Drugs Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Esophageal Cancer Drugs Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Fluorouracil
      • 1.4.3 Cisplatin
      • 1.4.4 Docetaxel
      • 1.4.5 Carboplatin
      • 1.4.6 Others
    • 1.5 Market by Application
      • 1.5.1 Global Esophageal Cancer Drugs Market Share by Application (2019-2025)
      • 1.5.2 Targeted Therapy
      • 1.5.3 Chemotherapy
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Esophageal Cancer Drugs Market Size
    • 2.2 Esophageal Cancer Drugs Growth Trends by Regions
      • 2.2.1 Esophageal Cancer Drugs Market Size by Regions (2019-2025)
      • 2.2.2 Esophageal Cancer Drugs Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 Esophageal Cancer Drugs Market Size by by Players
      • 3.1.1 Global Esophageal Cancer Drugs Revenue by by Players (2014-2019)
      • 3.1.2 Global Esophageal Cancer Drugs Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global Esophageal Cancer Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.2 Esophageal Cancer Drugs Key Players Head office and Area Served
    • 3.3 Key Players Esophageal Cancer Drugs Product/Solution/Service
    • 3.4 Date of Enter into Esophageal Cancer Drugs Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Esophageal Cancer Drugs Market Size by Type (2014-2019)
    • 4.2 Global Esophageal Cancer Drugs Market Size by Application (2014-2019)

    5 North America

    • 5.1 North America Esophageal Cancer Drugs Market Size (2014-2019)
    • 5.2 Esophageal Cancer Drugs Key Players in North America
    • 5.3 North America Esophageal Cancer Drugs Market Size by Type
    • 5.4 North America Esophageal Cancer Drugs Market Size by Application

    6 Europe

    • 6.1 Europe Esophageal Cancer Drugs Market Size (2014-2019)
    • 6.2 Esophageal Cancer Drugs Key Players in Europe
    • 6.3 Europe Esophageal Cancer Drugs Market Size by Type
    • 6.4 Europe Esophageal Cancer Drugs Market Size by Application

    7 China

    • 7.1 China Esophageal Cancer Drugs Market Size (2014-2019)
    • 7.2 Esophageal Cancer Drugs Key Players in China
    • 7.3 China Esophageal Cancer Drugs Market Size by Type
    • 7.4 China Esophageal Cancer Drugs Market Size by Application

    8 Japan

    • 8.1 Japan Esophageal Cancer Drugs Market Size (2014-2019)
    • 8.2 Esophageal Cancer Drugs Key Players in Japan
    • 8.3 Japan Esophageal Cancer Drugs Market Size by Type
    • 8.4 Japan Esophageal Cancer Drugs Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Esophageal Cancer Drugs Market Size (2014-2019)
    • 9.2 Esophageal Cancer Drugs Key Players in Southeast Asia
    • 9.3 Southeast Asia Esophageal Cancer Drugs Market Size by Type
    • 9.4 Southeast Asia Esophageal Cancer Drugs Market Size by Application

    10 India

    • 10.1 India Esophageal Cancer Drugs Market Size (2014-2019)
    • 10.2 Esophageal Cancer Drugs Key Players in India
    • 10.3 India Esophageal Cancer Drugs Market Size by Type
    • 10.4 India Esophageal Cancer Drugs Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Esophageal Cancer Drugs Market Size (2014-2019)
    • 11.2 Esophageal Cancer Drugs Key Players in Central & South America
    • 11.3 Central & South America Esophageal Cancer Drugs Market Size by Type
    • 11.4 Central & South America Esophageal Cancer Drugs Market Size by Application

    12 International Players Profiles

    • 12.1 Bristol-Myers Squibb Company
      • 12.1.1 Bristol-Myers Squibb Company Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Esophageal Cancer Drugs Introduction
      • 12.1.4 Bristol-Myers Squibb Company Revenue in Esophageal Cancer Drugs Business (2014-2019))
      • 12.1.5 Bristol-Myers Squibb Company Recent Development
    • 12.2 Eli Lilly and Company
      • 12.2.1 Eli Lilly and Company Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Esophageal Cancer Drugs Introduction
      • 12.2.4 Eli Lilly and Company Revenue in Esophageal Cancer Drugs Business (2014-2019)
      • 12.2.5 Eli Lilly and Company Recent Development
    • 12.3 F. Hoffmann-La Roche Ltd
      • 12.3.1 F. Hoffmann-La Roche Ltd Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Esophageal Cancer Drugs Introduction
      • 12.3.4 F. Hoffmann-La Roche Ltd Revenue in Esophageal Cancer Drugs Business (2014-2019)
      • 12.3.5 F. Hoffmann-La Roche Ltd Recent Development
    • 12.4 Merck & Co., Inc.
      • 12.4.1 Merck & Co., Inc. Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Esophageal Cancer Drugs Introduction
      • 12.4.4 Merck & Co., Inc. Revenue in Esophageal Cancer Drugs Business (2014-2019)
      • 12.4.5 Merck & Co., Inc. Recent Development
    • 12.5 Sanofi
      • 12.5.1 Sanofi Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Esophageal Cancer Drugs Introduction
      • 12.5.4 Sanofi Revenue in Esophageal Cancer Drugs Business (2014-2019)
      • 12.5.5 Sanofi Recent Development

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Product (2019-2025)
    • 13.2 Market Size Forecast by Application (2019-2025)
    • 13.3 Market Size Forecast by Regions
    • 13.4 North America
    • 13.5 Europe
    • 13.6 China
    • 13.7 Japan
    • 13.8 Southeast Asia
    • 13.9 India
    • 13.10 Central & South America

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 15.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Esophageal cancer is cancer arising from the esophagus—the food pipe that runs between the throat and the stomach.Symptoms often include difficulty in swallowing and weight loss.Other symptoms may include pain when swallowing, a hoarse voice, enlarged lymph nodes ("glands") around the collarbone, a dry cough, and possibly coughing up or vomiting blood.
      Various combinations of drugs such as fluorouracil, cisplatin, docetaxel, and carboplatin are involved in standard chemotherapy regimens for the treatment of esophageal cancer. These drugs are selected based on adverse drug reactions and cancer subtypes. To ensure patient access to available therapeutics, governments in developed countries are introducing reimbursement policies.
      In 2018, the global Esophageal Cancer Drugs market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Esophageal Cancer Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Esophageal Cancer Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

      The key players covered in this study
      Bristol-Myers Squibb Company
      Eli Lilly and Company
      F. Hoffmann-La Roche Ltd
      Merck & Co., Inc.
      Sanofi
      ...

      Market segment by Type, the product can be split into
      Fluorouracil
      Cisplatin
      Docetaxel
      Carboplatin
      Others

      Market segment by Application, split into
      Targeted Therapy
      Chemotherapy

      Market segment by Regions/Countries, this report covers
      North America
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Esophageal Cancer Drugs status, future forecast, growth opportunity, key market and key players.
      To present the Esophageal Cancer Drugs development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Esophageal Cancer Drugs are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
      Buy now